← All trials
NCT04386070
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 15, 2020
- Primary completion
- May 14, 2021
- Completion date
- May 14, 2026
- First posted
- May 13, 2020
- Last posted
- May 13, 2020
- Enrollment
- 6400
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of BirminghamLead sponsor
- Istituto Clinico Humanitas - Rozzano (MI), ItalyCollaborator
- University of LagosCollaborator
- University of the WitwatersrandCollaborator
- University of BirminghamOverall official - principal investigator
- University of EdinburghCollaborator
- University of Cape TownCollaborator
- Christian Medical College, Vellore, IndiaCollaborator
- Kigali Central University Hospital, RwandaCollaborator
- Hospital Espanol de VeracruzCollaborator
- Tamale Teaching Hospital, TamaleCollaborator
- Université d'Abomey-CalaviCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.